FIGS Is Up 12% in a Week. Is Its Raised Outlook Really That Good?
FIGS stock rose 12% after Q3 revenue grew 25.7% and the company raised its full-year outlook. Analysts increased price targets, with Barclays at $28 and KeyBanc at $27. FIGS expects 24% growth for 2026, up from 20%, and adjusted EBITDA margin of 15.8%. Analysts now expect 2027 EPS of $0.42, up from $0.38.
How this was made

The 30-second read
Why it matters
Recap provides no new data; traders gain no actionable insight beyond what was already known.
Market read
Low relevance; repeats prior earnings release without new information.
What to watch
Potential supply risk from Jordanian supplier blockage could affect Q2 2027 performance.
Background
The article summarizes FIGS' Q3 earnings, revenue growth, margin improvement, and raised full‑year outlook, all disclosed on Nov 5.
Ticker impact
Article recaps Q3 results and raised outlook that were released 8 days earlier; no new corporate action.
limited upside pressure as investors digest guidance; no immediate directional move expected
The piece only repeats already‑public earnings numbers and guidance, offering no new information to drive price.
Market effects
None; article focuses on a single company.
None
None
Counterpoint
Without a new catalyst, the stock may face profit‑taking after the 12% rally.
Key entities
- companyFIGS
Medical apparel maker (NASDAQ: FIGS).



